ONCOLYTICS BIOTECH INC.

Analyst Reco. Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Market Closed - Toronto S.E. Other stock markets 01:29:31 02/05/2024 am IST			5-day change	1st Jan Change
1.54 ^CAD	+0.65%		+7.69%	-13.97%

11/04	Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA	CI
11/04	Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Oncolytics Biotech to $5 From $15, Maintains Buy Rating	13/11	MT
Oncolytics Biotech Brief: Announcing Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep "Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate"	05/23/05	MT
Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate	05/23/05	CI
JonesTrading Initiates Oncolytics Biotech at Buy With $9 Price Target	24/23/24	MT
Canaccord Genuity Adjusts Price Target on Oncolytics Biotech to $5 From $6, Maintains Buy Rating	06/23/06	MT
Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting	07/22/07	CI
Oncolytics Biotech Brief: Reporting Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting	07/22/07	MT
Maxim Initiates Oncolytics Biotech With Buy Rating, Sets Price Target at $3	06/22/06	MT
RBC Capital Keeps OutperformSpeculative on Oncolytics Biotech	04/22/04	MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk Rating, $6 TP on Oncolytics Biotech	13/21/13	MT
ONCOLYTICS BIOTECH : HC Wainwright Starts Oncolytics Biotech at Buy With $15 Price Target	17/21/17	MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk on Oncolytics Biotech After Q3	13/20/13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer